SEC Form 4 · accession 0001213900-18-014532
AYTU BIOPHARMA, INC · AYTU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua R. Disbrow
Officer — Chief Executive Officer · Director
Period of report
Oct 24, 2018
Accepted (ET)
Oct 26, 2018 · 7:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385818
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 24, 2018 | A | 445,500 | — | A | 470,048 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These are restricted shares which vest on October 24, 2028, subject to earlier vesting in certain situations.
- F2Aggregate amount indicated reflects 20-for-1 reverse split and includes additional 7,975 post-split restricted shares previously issued.